Evidence map›Paper›PMID 27468210›Full record

ReviewWorld journal of gastroenterology2016

Pleiotropic effects of statins in the diseases of the liver.

Martin Janicko, Sylvia Drazilova, Daniel Pella, Jan Fedacko, Peter Jarcuska

Abstract readReview
PubMed Full text at PMC Publisher
In one paragraph

Review in World journal of gastroenterology, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 32 papers, 3 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
32citing papers in PubMed, 3 pooled it
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

32 citing papers in PubMed, 3 syntheses or guidelines pooled it.

  1. Pooled it
  2. Pooled it
  3. Pooled it
  4. Trial
  5. Article
  6. Article
  7. Article
  8. Article
  9. Review
  10. Review
  11. Review
  12. Review
  13. Review
  14. Article
  15. Article
  16. Article
  17. Pleiotropic effects of statins: A focus on cancer.Biochimica et biophysica acta. Molecular basis of disease · 2020
    Review
  18. Article
  19. Observational
  20. Screening for YAP Inhibitors Identifies Statins as Modulators of Fibrosis.American journal of respiratory cell and molecular biology · 2020
    Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

5 authors.

Martin JanickoMartin Janicko, Daniel Pella, Jan Fedacko, Peter Jarcuska, 1 Department of Internal medicine, Pavol Jozef Safarik University in Kosice, Louis Pasteur University hospital, 04001 Kosice, Slovakia.
Sylvia DrazilovaMartin Janicko, Daniel Pella, Jan Fedacko, Peter Jarcuska, 1 Department of Internal medicine, Pavol Jozef Safarik University in Kosice, Louis Pasteur University hospital, 04001 Kosice, Slovakia.
Daniel PellaMartin Janicko, Daniel Pella, Jan Fedacko, Peter Jarcuska, 1 Department of Internal medicine, Pavol Jozef Safarik University in Kosice, Louis Pasteur University hospital, 04001 Kosice, Slovakia.
Jan FedackoMartin Janicko, Daniel Pella, Jan Fedacko, Peter Jarcuska, 1 Department of Internal medicine, Pavol Jozef Safarik University in Kosice, Louis Pasteur University hospital, 04001 Kosice, Slovakia.
Peter JarcuskaMartin Janicko, Daniel Pella, Jan Fedacko, Peter Jarcuska, 1 Department of Internal medicine, Pavol Jozef Safarik University in Kosice, Louis Pasteur University hospital, 04001 Kosice, Slovakia.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Statins are a class of molecules that inhibit HMG CoA reductase. They are usually prescribed as a lipid lowering medication. However, there is accumulating evidence that statins have multiple secondary effects both related and unrelated to their lipid-lowering effect. This narrative review of the literature aims to provide the reader with information from clinical studies related to the effect of statin and statins' potential use in patients with liver diseases. In patients with advanced liver disease due to any etiology, statins exhibit an antifibrotic effect possibly through the prevention of hepatic sinusoidal microthrombosis. Two randomized controlled trials confirmed that statins decrease hepatic vein pressure gradient in patients with portal hypertension and improve the survival of patients after variceal bleeding. Lower rates of infections were observed in patients with cirrhosis who received statin treatment. Statins decrease the risk of hepatocellular carcinoma (HCC) in patients with advanced liver disease in general but particularly in patients with chronic hepatitis B and C. Statins in patients with chronic hepatitis C likely increase the virological response to the treatment with pegylated interferon and ribavirin and have the potential to decrease the rate of fibrosis. Finally, data from randomized controlled trials also confirmed that the addition of statin prolongs the survival of patients with advanced HCC even more than sorafenib. Statins are a very promising group of drugs especially in patients with liver disease, where therapeutic options can often be limited. Some indications, such as the prevention of re-bleeding from esophageal varices and the palliative treatment of HCC have been proven through randomized controlled trials, while additional indications still need to be confirmed through prospective studies.

Indexed as

Antiviral AgentsCarcinoma, HepatocellularEsophageal and Gastric VaricesGastrointestinal HemorrhageHepatitis B, ChronicHepatitis C, ChronicHumansHydroxymethylglutaryl-CoA Reductase InhibitorsHypertension, PortalLiver CirrhosisLiver NeoplasmsProtective FactorsAntiviral AgentsHydroxymethylglutaryl-CoA Reductase InhibitorsCirrhosisEsophageal varicesHepatitisHepatocellular carcinomaStatins

Identifiers

PMID27468210
PMCPMC4945979

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.